Nafagrel [DP 1904, SR 96325] is a thromboxane A2 synthetase inhibitor that was undergoing clinical trials with Daiichi Seiyaku, now Daiichi Pharmaceutical, for the diabetic angiopathies, lupus nephritis and Raynaud's disease in Japan. However the development of Nafagrel has been discontinued.

Midaglizole (also known as DG 5128) is a α2 adrenoceptor antagonist. Daiichi Pharmaceutical developed this drug as an oral antidiabetic agent and to treat asthma. However, further study of this drug was discontinued.

Ecabapide (DQ 2511) is a compound with antiulcer and gastroprokinetic activity. Evidence from basic studies in animal models suggests that the drug acts on peripheral mechanisms of neural control. In the stomach, ecabapide acts to suppress firing in vagal afferent nerves and thereby reduce the flow of sensory information into the dorsal vagal complex. The mechanism of action of ecabapide in suppressing discharge in vagal afferent terminals appears to mimic that of nitric oxide by stimulating formation of cGMP and activation of an inhibitory transduction cascade in the sensory fibres. In this respect the mechanism of its pro-kinetic action differs from other promoter agents. Ecabapide development has been discontinued.

Romurtide (Muroctasin) is a non-specific immune stimulant derived from muramyl dipeptide, which is obtained from gram-positive bacterial cell walls. Muroctasin stimulates macrophages, which release interleukin-l, which in turn increases production of colony-stimulating factors; muroctasin also evokes an increased production of neutrophils. It is used in Japan for chemotherapy-induced leukopenia.

Cetraxate is an oral gastrointestinal medication, mucosal protectant. Cetraxate might indirectly stimulate capsaicin-sensitive afferent nerves and increase mucosal blood flow, and that this may be a key mechanism underlying its gastroprotective action. Cetraxate prevents gastric mucosal blood flow decrease in H. pylori-infected patients. It is usually used to improve gastric mucosal lesion in acute gastritis or acute exacerbation of chronic gastritis and to treat gastric ulcer. The most commonly reported adverse reactions include constipation, rash, nausea, vomiting, dry mouth and diarrhea.

Midaglizole (also known as DG 5128) is a α2 adrenoceptor antagonist. Daiichi Pharmaceutical developed this drug as an oral antidiabetic agent and to treat asthma. However, further study of this drug was discontinued.

Nafagrel [DP 1904, SR 96325] is a thromboxane A2 synthetase inhibitor that was undergoing clinical trials with Daiichi Seiyaku, now Daiichi Pharmaceutical, for the diabetic angiopathies, lupus nephritis and Raynaud's disease in Japan. However the development of Nafagrel has been discontinued.

Nafagrel [DP 1904, SR 96325] is a thromboxane A2 synthetase inhibitor that was undergoing clinical trials with Daiichi Seiyaku, now Daiichi Pharmaceutical, for the diabetic angiopathies, lupus nephritis and Raynaud's disease in Japan. However the development of Nafagrel has been discontinued.

Cetraxate is an oral gastrointestinal medication, mucosal protectant. Cetraxate might indirectly stimulate capsaicin-sensitive afferent nerves and increase mucosal blood flow, and that this may be a key mechanism underlying its gastroprotective action. Cetraxate prevents gastric mucosal blood flow decrease in H. pylori-infected patients. It is usually used to improve gastric mucosal lesion in acute gastritis or acute exacerbation of chronic gastritis and to treat gastric ulcer. The most commonly reported adverse reactions include constipation, rash, nausea, vomiting, dry mouth and diarrhea.